S8 Ep6: FDA Approval Insights: Tremelimumab Plus Durvalumab and Chemotherapy in NSCLC
Dec 15, 2022
12:56
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
Dr Johnson discusses the FDA approval of tremelimumab plus durvalumab and chemotherapy in non–small cell lung cancer, key data from the POSEIDON trial, and the combination’s efficacy and tolerability in various patient populations.
OncLive® On Air